查詢結果分析
來源資料
相關文獻
- Nasopharyngeal Carcinoma Associated with Hemophagocytic Lymphohistiocytosis
- Detection of Human Papilloma Virus and Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma by Polymerase Chain Reaction
- Analysis of Epstein-Barr Virus DNA in Nude Mouse-Passaged Nasopharyngeal Carcinoma Tissues
- Serum Responses to the Combination of Epstein-Barr Virus Antigens in Patients with Nasopharyngeal Carcinoma in a Follow-up Study
- Clinical Application of Two New Serological Tests of Epstein-Barr Virus in Nasopharyngeal Carcinoma
- Prevalence of the Taiwan Variant of the Epstein-Barr Virus in Nasopharyngeal Carcinoma Patients and Normal Individuals
- 鼻咽癌與治療前EB病毒VCA抗體指數的關係
- Detection of Ebv in Tumor Tissue and Peripheral Blood by Polymerase Chain Reaction in Patients with Nasopharyngeal Carcinoma
- EB病毒相關疾病中的EB病毒Bam HI F DNA片段序列分析
- 鼻咽癌細胞株在EB病毒感染後其細胞素及生長因子基因的表現
頁籤選單縮合
題 名 | Nasopharyngeal Carcinoma Associated with Hemophagocytic Lymphohistiocytosis=鼻咽癌與嗜血性淋巴組織球血症 |
---|---|
作 者 | 吳旭; 黃懷正; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 2:1 2015.03[民104.03] |
頁 次 | 頁93-99 |
分類號 | 416.879 |
關鍵詞 | 鼻咽癌; 嗜血性淋巴組織球血症; EB病毒; Nasopharyngeal carcinoma; Hemophagocytic lymphohistiocytosis; Epstein-Barr virus; |
語 文 | 英文(English) |
中文摘要 | 背景:嗜血性淋巴組織球血症是一個少見致命率高的疾病。先天基因缺陷、感染、惡性血液疾病或腫瘤、或自體免疫疾病都可能導致嗜血性淋巴組織球血症的發生。與鼻咽癌相關的嗜血性淋巴組織球血症的病例報告很少見。病例報告: 56歲男性病例有復發且多處發生轉移的鼻咽癌且後續病發嗜血性淋巴組織球血症。病患發生了持續發燒、脾臟腫大、血球減少、血中鐵蛋白及肝指數上升、黃疸及骨髓抹片中發現嗜血性淋巴組織球。他同時併有極高的血中 Epstein-Barr (EB)病毒量。他被我們診斷為 EB病毒或鼻咽癌相關之嗜血性淋巴組織球血症。我們使用 etoposide、 cisplatin及靜脈免疫球蛋白注射治療。雖然最後病患在血球數開始恢復前因吸入性肺炎過世,但在過世前肝指數及黃疸卻逐漸改善。結論:嗜血性淋巴組織球血症是個高致死性的疾病。醫師於臨床上懷疑病患罹患此症,必須儘快給予 etoposide為基底的化學治療,並同時治療導致嗜血性淋巴組織球血症的病因。在本病例報告中,病患的嗜血性淋巴組織球血症可能與 EB病毒或鼻咽癌相關,因此我們同時治療兩個病因,病患的症狀因此改善。嗜血性淋巴組織球血症與 EB病毒和鼻咽癌之間的相關性是後續值得探討的議題。 |
英文摘要 | Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare disease with high fatality. It can be genetic, or it can be associated with infection, malignancy or autoimmune disorders. Cases of nasopharyngeal carcinoma (NPC) associated with HLH are rare. Case Report: A 56 year-old man with recurrent NPC with metastases had concurrent HLH. The patient presented with fever, splenomegaly, cytopenia in three lineages, elevated ferritin, elevated liver transaminases, hyperbilirubinemia, and hemophagocytosis in bone marrow. He also had a very high serum Epstein-Barr (EB) viral load. We diagnosed HLH in this patient, believing it to be associated with either EB virus or NPC. Following treatment with etoposide, cisplatin and intravenous immunoglobulin, the levels of liver transaminases and bilirubin decreased, but the patient’s pancytopenia did not improve before he died of aspiration pneumonia 6 months after the diagnosis of NPC. Conclusions: HLH is a disease with high fatality. Whenever there is a degree of clinical suspicion for HLH, etoposide-based chemotherapy should be started as soon as possible, and the underlying causes of the disease should be treated. We report this patient with NPC and HLH, which can be associated with either EBV or NPC. We treated both etiologies, and the patient’s symptoms and liver function improved. The interactions between EBV, NPC, and HLH are interesting and merit further investigation. |
本系統中英文摘要資訊取自各篇刊載內容。